Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
posaconazole
posaconazole
- Restricted ID & Oncology based on indication
- Non-formulary Miscellaneous Program Formulary
Last updated: Jul. 17, 2024
- Formulary, Not Routinely Stocked: Noxafil IV --> 18 mg/mL
Posaconazole IV is restricted to ID in immunocompromised patients for treatment of invasive fungal infections due to aspergillosis or mucormycosis, or in patients that have failed/cannot tolerate other agents. And for use by Oncology & ID prescribers in patients with AML or MDS unable to tolerate tablets for prophylaxis against invasive fungal infections. Not routinely stocked.
Posaconazole tablets are formulary, restricted to Oncology & ID prescribers for prophylaxis against invasive fungal infections in patients with AML or MDS.
If oral treatment is needed, CRESEMBA is a similar drug that is classified as formulary, restricted to Infectious Disease. No automatic interchange is approved. Contact the physician for an alternative.
Posaconazole suspension is classified as non-formulary, not stocked.
Reviewed: November 14, 2006 (suspension), and April 22, 2014 (ER tablets), and November 18, 2014 (injection)
Updated: 26 May 2015 (tablet, IV, suspension), and 28 March 2017 (IV), June 2022 (Prophylaxis)